ALMIRALL SA ORDINARY SHARES SPAIN (OTCMKTS:LBTSF) registered an increase of 11.92% in shares shorted. FINRA published shares shorted of LBTSF’s total 228,100 shares. Previously was reported up change of 11.92% from 203,800 shares.

$17.03 was the last price.Since April 2, 2018 it’s 0.00% up thus . The stock underperformed the S&P 500 by 4.37%.

Almirall, S.A., a pharmaceutical company, researches, develops, makes, and sells medicines and medical devices worldwide.The firm is worth $2.96 billion. The firm offers its products for dermatological diseases comprising actinic keratosis, psoriasis, eczema, and skin infections, as well as for multiple sclerosis; respiratory; nervous system; and other therapeutic areas.Last it reported negative earnings. The Company’s strategic brands include ACTIKERALL, BALNEUM, SATIVEX, SOLARAZE, and DECODERM.

A couple more Almirall, S.A. (OTCMKTS:LBTSF) news were brought out by: Seekingalpha.com which released on September 19, 2018 “Almirall’s tildrakizumab OK’d in Europe for plaque psoriasis – Seeking Alpha”, also Seekingalpha.com on February 25, 2019 brought out “Almirall SA 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha”, the next Seekingalpha.com is “Platinum Asset Management Quarterly Report September 30, 2018 – Seeking Alpha” on October 25, 2018. Seekingalpha.com has article titled “UCB Needs Clinical Success To Drive Upside – Seeking Alpha”.